Pila Pharma

Pila Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pila Pharma (PILA.ST) as of Oct 27, 2026 is 54.47 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 69.59 % — a change of -21.73% (lower).

FCF Conversion

54.47 %

YoY

-21.73%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pila Pharma is 2025 54.47 % . FCF Conversion Rate (FCF/EBITDA) of Pila Pharma was 2024 69.59 % . It decreases by -21.73% lower compared to the previous year.

The Pila Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
138.29 SEK
Jan 1, 2019
58.12 SEK
Jan 1, 2020
18.90 SEK
Jan 1, 2021
54.42 SEK
Jan 1, 2022
33.95 SEK
Jan 1, 2023
48.88 SEK
Jan 1, 2024
69.59 SEK
Jan 1, 2025
54.47 SEK
The Pila Pharma FCF Conversion history
YEARFCF ConversionYoY
54.47 %-21.73%
69.59 %+42.37%
48.88 %+43.98%
33.95 %-37.61%
54.42 %+187.90%
18.90 %-67.48%
58.12 %-57.97%
138.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pila Pharma Stock analysis

What does Pila Pharma do? Pila Pharma AB develops pharmaceutical products, focusing on XEN-D0501, a TRPV1 antagonist for type 2 diabetes treatment. The company conducts phase 2 clinical trials, including PP-CT01 and PP-CT02, which confirmed XEN-D0501's tolerability and potential for fewer side effects compared to existing treatments. Pila Pharma AB generates revenue through research and development of its patent-protected product candidate, targeting early-stage diabetes patients requiring oral medication to restore insulin production and lower blood sugar levels. The firm's primary product, XEN-D0501, is an orally administered tablet designed for early diabetes management. Clinical trials have shown positive results, supporting the product's safety profile and efficacy. Pila Pharma AB's business model centers on advancing its proprietary drug candidate through clinical development to secure regulatory approval and commercialization in the pharmaceutical market. Pila Pharma AB targets healthcare providers and patients with type 2 diabetes seeking innovative treatment options. The company's focus on phase 2 clinical trials positions it to address unmet medical needs in diabetes care, leveraging its patent-protected technology to differentiate XEN-D0501 from competitors. The firm's revenue stream depends on successful clinical outcomes leading to market entry of XEN-D0501. Pila Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pila Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Pila Pharma is 54.47 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pila Pharma changed from 69.59 % to 54.47 %, representing a -21.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pila Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pila Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Pila Pharma

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pila Pharma